Overall market sentiment has been down on Omeros Corporation (OMER) stock lately. OMER receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With OMER Stock Today?
Omeros Corporation (OMER) stock is lower by -1.38% while the S&P 500 is up 0.05% as of 3:31 PM on Tuesday, Apr 27. OMER has fallen -$0.25 from the previous closing price of $18.15 on volume of 1,757,670 shares. Over the past year the S&P 500 is up 45.55% while OMER is up 8.48%. OMER lost -$2.41 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Omeros Corporation click here.
More About Omeros Corporation
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
Click Here to get the full Stock Score Report on Omeros Corporation (OMER) Stock.
